FDA warned Davati Medical Supply for selling unapproved, unlicensed FLUZALP Quadrivalent influenza vaccine online in the U.S.
What happened
FDA reviewed www.davatimedical.com on June 22, 2021, and found the site directed consumers to contact Davati to buy FLUZALP Quadrivalent influenza vaccine, represented as made by Anzalp Pharmasolutions. FDA said the product is intended to prevent or treat influenza in people but is not approved or licensed for U.S. sale; the website also claimed FDA tests each batch before release.
What FDA found
Davati offered an influenza vaccine for sale in the U.S. without FDA approval as a new drug.
section 505 of the FD&C Act, 21 U.S.C. § 355The product was misbranded because it was offered with claims that misrepresented it as safe and effective for influenza prevention.
section 502 of the FD&C Act, 21 U.S.C. § 352The product was an unlicensed biological product because no biologics license was in effect.
section 351 of the PHS Act, 42 U.S.C. § 262There was no approved biologics license application or investigational new drug application in effect for the product.
21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312Introducing or delivering the product into interstate commerce was prohibited.
sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
What FDA wants
FDA tells Davati to stop selling the product immediately and, within 48 hours, email CBER with the steps taken, an explanation of how recurrence will be prevented, and supporting documents. If it cannot fully correct the matter in 48 hours, it must state why and give a timeline.
Who should pay attention
- clinics, pharmacies, and online sellers considering imported flu vaccines
- U.S. distributors and importers of biologics
- companies sourcing vaccines from Anzalp Pharmasolutions or Davati
This is a summary. Read the original letter on fda.gov.